1. Introduction {#sec1}
===============

Liver cancer is one of the most common digestive cancers in the world \[[@B1]\]. Although there have been improvements in clinical treatments in recent years, there have not been significant improvements in the prognosis of affected patients. There is an urgent need to identify novel prognostic biomarkers for liver cancer so that treatment selection can be improved.

Metabolic reprogramming is one of the hallmarks of cancer. Oxoglutarate dehydrogenase-like (*OGDHL*) is an essential regulatory gene and a putative tumor suppressor gene. The OGDHL protein is an isoform of 2-oxoglutarate dehydrogenase and functions as the first and rate-limiting step of the multienzyme OGDH complex (OGDHC), which degrades glucose and glutamate \[[@B2], [@B3]\]. Previous studies have reported enrichment of OGDHL in the brain and undetectable levels in the heart \[[@B2]\]. Subsequent studies examined the downregulation and methylation of *OGDHL* in breast cancer \[[@B4]\], cervical cancer \[[@B5]\], and colorectal cancer \[[@B6]\].

However, the diagnostic value, prognostic value, and role of OGDHL in liver cancer remain unknown. In this study, we compared *OGDHL* expression in cancerous and healthy liver tissues and evaluated its diagnostic value by receiver operating characteristic (ROC) analysis. We also examined the correlation of *OGDHL* expression with clinical features and performed survival analysis using the Cox model to assess its function as an independent prognostic indicator in liver cancer.

2. Materials and Methods {#sec2}
========================

2.1. Data Mining of The Cancer Genome Atlas Database {#sec2.1}
----------------------------------------------------

The RNAseq data of *OGDHL* and clinical information were downloaded from The Cancer Genome Atlas (TCGA) dataset. No ethical approval was necessary because these are anonymized public datasets.

2.2. Statistical Analysis {#sec2.2}
-------------------------

All data analyses were performed using R (version 3.5.1) \[[@B7]\] and several R extensions. Boxplots were used to display expression of *OGDHL* mRNA. The chi-squared test was used to evaluate the correlation between *OGDHL* expression and the clinical features of patients. The pROC package was used to perform ROC analysis, to determine the optimal *OGDHL* cut-off point and to assess the diagnostic value of *OGDHL* expression by calculation of the area under the curve (AUC) \[[@B8]\]. Survival curves were plotted for different groups of patients, and curves were compared using the log-rank test. A survival package executed univariate and multivariate Cox analyses \[[@B9]\].

Ggplot2 was used for data visualization \[[@B10]\].

2.3. Gene Set Enrichment Analysis {#sec2.3}
---------------------------------

Gene set enrichment analysis (GSEA) was used to assess the distributions of predefined gene sets in gene lists sorted by phenotype correlation and to determine the contribution of different genes to phenotype \[[@B11], [@B12]\]. This analysis was performed using the GSEA 3.0 software and the gene set of "h.all.v6.2.symbols.gmt" from the Molecular Signatures Database. The normalized enrichment score (NES) was obtained from 1000 permutations.

3. Results {#sec3}
==========

3.1. Patient Characteristics and OGDHL Expression {#sec3.1}
-------------------------------------------------

[Table 1](#tab1){ref-type="table"} shows the clinical characteristics of the 373 liver cancer patients from TCGA dataset, including age, sex, histological type, histologic grade, stage, TNM classification, receipt of radiation therapy, presence of residual tumor, vital status, and relapse. Analysis of *OGDHL* expression ([Figure 1](#fig1){ref-type="fig"}) indicated significantly lower expression in cancerous liver tissues than adjacent normal tissues (*P* \< 2.2 × 10^−16^). In addition, *OGDHL* expression was inversely correlated with more advanced histologic grade (*P* = 2.6 × 10^−8^), stage (*P* = 0.0014), T classification (*P* = 0.002), M classification (*P* = 0.043), and age (*P* = 0.0016) but positively correlated with longer survival (*P* = 0.035).

3.2. Diagnostic Capability of OGDHL Expression and Correlation with Clinical Features {#sec3.2}
-------------------------------------------------------------------------------------

We performed receiver operating characteristic (ROC) analysis to determine the diagnostic value of *OGDHL* expression ([Figure 2](#fig2){ref-type="fig"}). *OGDHL* expression had excellent diagnostic value overall (AUC = 0.909) and was also able to distinguish noncancerous tissue from stage I cancer (AUC = 0.885), stage II cancer (AUC = 0.920), stage III cancer (AUC = 0.949), and stage IV cancer (AUC = 0.998). We also found that low *OGDHL* expression correlated with more advanced patient age (*P* = 0.009), histologic grade (*P* = 0.000), stage (*P* = 0.015), T classification (*P* = 0.020), and poor survival (*P* = 0.037) ([Table 2](#tab2){ref-type="table"}).

3.3. Correlation of OGDHL Expression with Survival {#sec3.3}
--------------------------------------------------

Survival analysis showed that patients with lower *OGDHL* levels had shorter overall survival (OS), and subgroup analysis indicated this relationship also held for patients with grade G1/G2, stage I/II, T3, N0, and M0 cancers ([Figure 3](#fig3){ref-type="fig"}). In addition, patients with lower *OGDHL* levels had shorter relapse-free survival, and subgroup analysis indicated this relationship also held for patients with grade G1/G2, stage III/IV, T1, T3, N0, and M1 cancers ([Figure 4](#fig4){ref-type="fig"}).

3.4. Low OGDHL as an Independent Risk Factor for Survival {#sec3.4}
---------------------------------------------------------

We initially used univariate Cox analysis to select the potential variables for multivariable analysis (Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}). The subsequent multivariate Cox regression analysis indicated that low *OGDHL* expression was an independent risk factor for poor OS (hazard ratio (HR) = 1.75; 95% confidence interval (CI) = 1.2 to 2.54; *P* = 0.003) and poor relapse-free survival (HR = 1.58; 95%CI = 1.09 to 2.3; *P* = 0.016).

3.5. OGDHL-Related Signaling Pathways {#sec3.5}
-------------------------------------

We used GSEA to identify the signaling pathway(s) activated in HCC by comparing data sets that had low and high expression of *OGDHL* ([Table 5](#tab5){ref-type="table"}, [Figure 5](#fig5){ref-type="fig"}). The results indicate significant differences in the enrichment of the MSigDB Collection (false discovery rate \< 0.25, nominal *P* value \< 0.05; h.all.v6.2.symbols.gmt). We then identified the most significant signaling pathways based on NES. These results show that E2F targets, the mitotic spindle, and the G2M checkpoint were enriched in the *OGDHL* low-expression phenotype.

4. Discussion {#sec4}
=============

Our team previously used TCGA to identify diagnostic and prognostic biomarkers for several cancers \[[@B13]--[@B19]\]. In the present study, we found that *OGDHL* had low expression in liver cancer and that low expression correlated with more advanced patient age, histologic grade, stage, T classification, and shorter survival. In addition, our multivariable analysis indicated that low *OGDHL* expression was a significant diagnostic and prognostic biomarker for liver cancer.

Previous research identified OGDHL as an isoform of 2-oxoglutarate dehydrogenase, which regulated the degradation of glucose and glutamate \[[@B3]\]. An initial study of OGDHL function found enrichment of this protein in the brain but undetectable levels in the heart \[[@B2]\]. Subsequent studies focused on the relationship of *OGDHL* expression in several cancers and reported low expression in breast cancer \[[@B4]\], cervical cancer \[[@B5]\], and colorectal cancer \[[@B6]\]. Consistent with these results, we found low expression of *OGDHL* in liver cancer. Moreover, our ROC analysis showed that *OGDHL* expression had good diagnostic performance for patients with different stages of liver cancer, supporting its clinical use as a diagnostic biomarker. *OGDHL* expression also gradually decreased as histologic grade increased from G1 to G4, as stage increased from I to III, and as T classification increased from T1 to T3. The reason for the slightly higher expression in patients with the stage IV and T4 liver cancer is unknown, but it may be because we only analyzed a small number of patients with advanced cancer. We also found lower *OGDHL* expression in deceased than living patients, suggesting that OGDHL expression may be useful as a prognostic indicator.

Several previous studies have examined the functions of OGDHL. For example, Bunik and Degtyarev reported that OGDHL was located in the mitochondria (as predicted based on its sequence) and was an isoform of 2-oxoglutarate dehydrogenase \[[@B3]\]. Fujisawa et al. found that OGDHL functioned in adenylate kinase 4- (AK4-) regulated mitochondrial activity \[[@B20]\]. Yoon et al. identified nardilysin (NRD1) as a mitochondrial cochaperone for OGDH \[[@B21]\]. Sherrill et al. reported that certain variants of *OGDHL* lead to mitochondrial dysfunction and eosinophilic esophagitis \[[@B22]\]. Sen et al. found that OGDHL functioned as an antiproliferative gene and inhibited tumorigenesis *via* the AKT signaling pathway \[[@B5]\]. In conjunction with our results, this suggests that the downregulation of OGDHL, which alters mitochondrial function and increases cell proliferation, might explain our observation of a correlation of low *OGDHL* expression with more advanced cancer.

Many studies of *OGDHL* that examined its regulation of cancer have focused on methylation of its promoter region \[[@B4], [@B6], [@B23], [@B24]\]. However, no previous studies have examined its clinical significance or prognostic value. We found that patients with liver cancer who had lower *OGDHL* expression had shorter OS and shorter relapse-free survival. Our subgroup analysis indicated that *OGDHL* had prognostic value for specific groups of patients in predicting OS (G1/G2, I/II, T3, N0, and M0) and in specific group of patients for predicting relapse-free survival (G1/G2, III/IV, T1, T3, N0, and M1). These results suggest that *OGDHL* may be useful as a prognostic biomarker for liver cancer.

This study is the first to identify *OGDHL* as a novel diagnostic and prognostic biomarker for liver cancer. The targets of this protein appear to be the mitotic spindle, G2M checkpoint, and E2F. However, a limitation of this study is that we only examined a small number of patients with advanced-stage liver cancer; the cause of higher OGDHL expression in late stage liver cancer patients needs to be explored in the future study.

5. Conclusion {#sec5}
=============

In conclusion, we found low expression of *OGDHL* in liver cancer and that low expression correlated with advanced patient age, histologic grade, stage, T classification, and poor survival. We also found that *OGDHL* expression had value as a diagnostic and prognostic indicator of liver cancer and that low *OGDHL* expression was an independent prognostic risk factor. Our GSEA analysis indicated that the potential targets of OGDHL were the mitotic spindle, G2M checkpoint, and E2F. This study is the first to identify the diagnostic and prognostic value of *OGDHL* in liver cancer, and our results indicate that *OGDHL* might be useful as a novel biomarker for liver cancer.

These results require verification by studies of larger populations.
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###### 

Clinical characteristics of the liver cancer patients.

  Characteristics                     Number of pts (%)
  ----------------------------------- -------------------
  Age                                 
   \<55                               117 (31.45)
   ≥55                                255 (68.55)
  Gender                              
   Female                             121 (32.44)
   Male                               252 (67.56)
  Histological type                   
   Fibrolamellar carcinoma            3 (0.8)
   Hepatocellular carcinoma           363 (97.32)
   Hepatocholangiocarcinoma (mixed)   7 (1.88)
  Histologic grade                    
   NA                                 5 (1.34)
   G1                                 55 (14.75)
   G2                                 178 (47.72)
   G3                                 123 (32.98)
   G4                                 12 (3.22)
  Stage                               
   NA                                 24 (6.43)
   I                                  172 (46.11)
   II                                 87 (23.32)
   III                                85 (22.79)
   IV                                 5 (1.34)
  T classification                    
   NA                                 2 (0.54)
   T1                                 182 (48.79)
   T2                                 95 (25.47)
   T3                                 80 (21.45)
   T4                                 13 (3.49)
   TX                                 1 (0.27)
  N classification                    
   NA                                 1 (0.27)
   N0                                 253 (67.83)
   N1                                 4 (1.07)
   NX                                 115 (30.83)
  M classification                    
   M0                                 267 (71.58)
   M1                                 4 (1.07)
   MX                                 102 (27.35)
  Radiation therapy                   
   NA                                 25 (6.7)
   No                                 340 (91.15)
   Yes                                8 (2.14)
  Residual tumor                      
   NA                                 7 (1.88)
   R0                                 326 (87.4)
   R1                                 17 (4.56)
   R2                                 1 (0.27)
   RX                                 22 (5.9)
  Vital status                        
   Deceased                           130 (34.85)
   Living                             243 (65.15)
  Relapse                             
   No                                 179 (55.94)
   Yes                                141 (44.06)
  OGDHL                               
   High                               270 (72.39)
   Low                                103 (27.61)

###### 

Relationship between the clinical features and OGDHL expression in liver cancer patients.

  Clinical characteristics           Variable                  No. of patients   OGDHL expression   *χ* ^2^   *P* value                    
  ---------------------------------- ------------------------- ----------------- ------------------ --------- ----------- ------- -------- -------
  Age                                \<55                      117               74                 27.41     43          42.16   6.802    0.009
  ≥55                                255                       196               72.59              59        57.84                        
                                                                                                                                           
  Gender                             Female                    121               86                 31.85     35          33.98   0.072    0.788
  Male                               252                       184               68.15              68        66.02                        
                                                                                                                                           
  Histological type                  Fibrolamellar carcinoma   3                 3                  1.11      0           0       1.809    0.617
  Hepatocellular carcinoma           363                       261               96.67              102       99.03                        
  Hepatocholangiocarcinoma (mixed)   7                         6                 2.22               1         0.97                         
                                                                                                                                           
  Histologic grade                   G1                        55                41                 15.47     14          13.59   25.673   0.000
  G2                                 178                       147               55.47              31        30.1                         
  G3                                 123                       69                26.04              54        52.43                        
  G4                                 12                        8                 3.02               4         3.88                         
                                                                                                                                           
  Stage                              I                         172               135                54        37          37.37   10.116   0.015
  II                                 87                        60                24                 27        27.27                        
  III                                85                        51                20.4               34        34.34                        
  IV                                 5                         4                 1.6                1         1.01                         
                                                                                                                                           
  T classification                   T1                        182               144                53.73     38          36.89   10.765   0.020
  T2                                 95                        64                23.88              31        30.1                         
  T3                                 80                        49                18.28              31        30.1                         
  T4                                 13                        10                3.73               3         2.91                         
  TX                                 1                         1                 0.37               0         0                            
                                                                                                                                           
  N classification                   N0                        253               178                65.93     75          73.53   3.519    0.149
  N1                                 4                         2                 0.74               2         1.96                         
  NX                                 115                       90                33.33              25        24.51                        
                                                                                                                                           
  M classification                   M0                        267               186                68.89     81          78.64   3.523    0.156
  M1                                 4                         3                 1.11               1         0.97                         
  MX                                 102                       81                30                 21        20.39                        
                                                                                                                                           
  Radiation therapy                  No                        340               245                97.22     95          98.96   0.320    0.572
  Yes                                8                         7                 2.78               1         1.04                         
                                                                                                                                           
  Residual tumor                     R0                        326               239                90.53     87          85.29   4.018    0.245
  R1                                 17                        12                4.55               5         4.9                          
  R2                                 1                         1                 0.38               0         0                            
  RX                                 22                        12                4.55               10        9.8                          
                                                                                                                                           
  Vital status                       Deceased                  130               85                 31.48     45          43.69   4.371    0.037
  Living                             243                       185               68.52              58        56.31                        

###### 

Univariate analysis and multivariate analysis of liver cancer patients\' overall survival.

  Parameters          Univariate analysis   Multivariate analysis                              
  ------------------- --------------------- ----------------------- ------- ------ ----------- -------
  Age                 1                     0.69-1.45               0.997                      
  Gender              0.8                   0.56-1.14               0.220                      
  Histological type   0.99                  0.27-3.66               0.986                      
  Histologic grade    1.04                  0.84-1.3                0.698                      
  Stage               1.38                  1.15-1.66               0.001   0.83   0.67-1.04   0.105
  T classification    1.66                  1.39-1.99               0.000   1.84   1.46-2.32   0.000
  N classification    0.73                  0.51-1.05               0.086                      
  M classification    0.72                  0.49-1.04               0.077                      
  Radiation therapy   0.51                  0.26-1.03               0.060                      
  Residual tumor      1.42                  1.13-1.8                0.003   1.38   1.08-1.77   0.011
  OGDHL               1.93                  1.34-2.79               0.000   1.75   1.2-2.54    0.003

###### 

Univariate analysis and multivariate analysis of liver cancer patients\' relapse-free survival.

  Parameters          Univariate analysis   Multivariate analysis                              
  ------------------- --------------------- ----------------------- ------- ------ ----------- -------
  Age                 0.9                   0.63-1.28               0.550                      
  Gender              0.99                  0.7-1.41                0.966                      
  Histological type   2.02                  0.66-6.24               0.220                      
  Histologic grade    0.98                  0.8-1.21                0.883                      
  Stage               1.66                  1.38-1.99               0.000   1.09   0.85-1.41   0.497
  T classification    1.78                  1.49-2.12               0.000   1.69   1.3-2.19    0.000
  N classification    0.97                  0.67-1.4                0.874                      
  M classification    1.17                  0.79-1.74               0.432                      
  Radiation therapy   0.74                  0.26-2.16               0.584                      
  Residual tumor      1.28                  1.01-1.61               0.042   1.3    1.03-1.66   0.030
  OGDHL               1.66                  1.15-2.39               0.007   1.58   1.09-2.3    0.016

###### 

Gene sets enriched in phenotype high.

  NAME                       ES      NES     NOM *P* value   FDR *q* value
  -------------------------- ------- ------- --------------- ---------------
  HALLMARK_MITOTIC_SPINDLE   0.608   1.963   0.000           0.027
  HALLMARK_G2M_CHECKPOINT    0.763   1.930   0.000           0.019
  HALLMARK_E2F_TARGETS       0.748   1.881   0.002           0.020

Notes: gene sets with NOM *P* value \< 0.05 and FDR *q* value \< 0.25 are considered as significant. Abbreviations: FDR: false discovery rate; NES: normalized enrichment score; NOM: nominal.
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